Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 26 for:    astra zeneca strong

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03060512
Recruitment Status : Completed
First Posted : February 23, 2017
Results First Posted : July 13, 2018
Last Update Posted : July 13, 2018
Sponsor:
Collaborator:
QuintilesIMS, Inc.
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.

Condition or disease Intervention/treatment Phase
Opioid Induced Constipation Drug: Polyethylene Glycol 3350 Drug: Movantik Phase 4

Detailed Description:
This study is a prospective, randomized, open-label crossover study consisting of a 1-week washout period, a 2-week treatment period, another 1-week washout and a final 2-week treatment period. The study will assess the overall patient preference Movantik versus Polyethylene Glycol 3350 for the treatment of their opioid-induced constipation. This study will also evaluate the reasons for patient preference (only among subjects who indicate a preference), patient global impression of change, and change in bowel function over the treatment periods measured by Bowel Function Index. Patient's bowel movement diary will also be collected during the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 276 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment
Actual Study Start Date : March 2, 2017
Actual Primary Completion Date : August 23, 2017
Actual Study Completion Date : August 23, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Arm Intervention/treatment
Active Comparator: Crossover Group 1

Crossover Group Movantik to Polyethylene Glycol 3350

2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout.

Drug: Polyethylene Glycol 3350

Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.

Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Other Name: MiraLAX

Drug: Movantik

Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.

Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Other Name: Naloxegol

Active Comparator: Crossover Group 2

Crossover group Polyethylene Glycol 3350 to Movantik

2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout.

Drug: Polyethylene Glycol 3350

Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.

Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Other Name: MiraLAX

Drug: Movantik

Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.

Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Other Name: Naloxegol




Primary Outcome Measures :
  1. Patient Reported Preference for Movantik or PEG 3350 for Opioid-induced Constipation (OIC) Treatment [ Time Frame: From Visit 2 (Day 1) of Treatment Period 1 to Visit 5 (Day 36) of Treatment Period 2 (end of study). ]
    The Patient Preference Assessment was conducted at Visit 5 using a 7-point scale in subjects with chronic non-cancer pain. The 3 categories were formed by collapsing the 7-point rating scale to: 1. Prefer Movantik (including Strong preference for Movantik, Moderate preference for Movantik, Slight preference for Movantik), 2. No preference, and 3. Prefer PEG 3350 (including Strong preference for PEG 3350, Moderate preference for PEG 3350, and Slight preference for PEG 3350). The number of subjects in each category is presented for the total number of subjects in the Per-Protocol (PP) Set.

  2. Patient Reported Preference for Movantik or PEG 3350 for OIC Treatment by Treatment Sequence [ Time Frame: From Visit 2 (Day 1) of Treatment Period 1 to Visit 5 (Day 36) of Treatment Period 2 (end of study). ]
    The Patient Preference Assessment was conducted at Visit 5 using a 7-point scale in subjects with chronic non-cancer pain. The following categories were the possible responses: Strong preference for Movantik, Moderate preference for Movantik, Slight preference for Movantik, No preference, Slight preference for PEG 3350, Moderate preference for PEG 3350 and Strong preference for PEG 3350. Prefer Movantik included subjects in the categories Strong preference for Movantik, Moderate preference for Movantik and Slight preference for Movantik. Prefer PEG 3350 included subjects in the categories Strong preference for PEG 3350, Moderate preference for PEG 3350 and Slight preference for PEG 3350. Preference for Period 1 treatment and Preference for Period 2 treatment included subjects who preferred the first and second treatments respectively taken within a given treatment sequence. The number of subjects in each category is presented per treatment sequence for subjects in the PP Set.


Secondary Outcome Measures :
  1. Patient Reported Influence of Each Medication Characteristic Median Scores That Contributed to Their Overall Preference for Movantik or PEG 3350 [ Time Frame: From Visit 2 (Day 1) of Treatment Period 1 to Visit 5 (Day 36) of Treatment Period 2 (end of study). ]

    In order to assess the reason for patient preference of Movantik or PEG 3350, subjects reported on the influence of 5 medication characteristics using a 4-point rating scale. The following were the scale options: efficacy ('worked better to relieve my OIC'), tolerability ('tolerated better'), convenience ('was more convenient'), works quickly ('worked quickly') and works predictably ('worked predictably'). For each characteristic, influence scores were rated as: 0 = No influence, 1 = Mildly influenced, 2 = Moderately influenced or 3 = Strongly influenced. The scale range for each characteristic was from 0 to 3, and the median score for each characteristic is presented for the overall PP Set according to which treatment was preferred.

    The assessment was only completed by subjects who indicated an overall preference.


  2. Patient Reported Influence of Each Medication Characteristic Individual Category Results That Contributed to Their Overall Preference for Movantik or PEG 3350 [ Time Frame: From Visit 2 (Day 1) of Treatment Period 1 to Visit 5 (Day 36) of Treatment Period 2 (end of study). ]

    In order to assess the reason for patient preference of Movantik or PEG 3350, subjects reported on the influence of 5 medication characteristics using a 4-point rating scale. The following were the scale options: efficacy ('worked better to relieve my OIC'), tolerability ('tolerated better'), convenience ('was more convenient'), works quickly ('worked quickly') and works predictably ('worked predictably'). For each characteristic, influence scores were rated as: 0 = No influence, 1 = Mildly influenced, 2 = Moderately influenced or 3 = Strongly influenced. The scale range for each characteristic was from 0 to 3, and the number of subjects in each characteristic category is presented for the overall PP Set according to which treatment was preferred.

    The assessment was only completed by subjects who indicated an overall preference.


  3. Patient Global Impression of Change (PGIC) Questionnaire to Compare the Impact of Movantik and PEG 3350 on OIC Symptoms [ Time Frame: At Visit 3 (Day 15) of Treatment Period 1 and Visit 5 (Day 36) of Treatment Period 2. ]

    PGIC was measured on a 7-point scale at the end of each two-week treatment period to assess the subject's impression of the effectiveness of the treatment received for OIC. The scoring was as follows: 1 = No change (or condition has gotten worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real difference; 5 = Moderately better, and a slight but noticeable change; 6 = Better and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better and a considerable improvement that has made all the difference. The score range is from 1 to 7, with 1 indicating the least improvement and 7 indicating the greatest improvement in OIC symptoms.

    Mean score results are presented for each treatment for Visits 3 and 5.


  4. PGIC Questionnaire Individual Item Results to Compare the Impact of Movantik and PEG 3350 on OIC Symptoms [ Time Frame: At Visit 3 (Day 15) of Treatment Period 1 and Visit 5 (Day 36) of Treatment Period 2. ]

    PGIC was measured on a 7-point scale at the end of each two-week treatment period to assess the subject's impression of the effectiveness of the treatment received for OIC. The subjects selected one of the following PGIC items as their response: 1 = No change (or condition has gotten worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real differences; 5 = Moderately better, and a slight but noticeable change; 6 = Better and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better and a considerable improvement that has made all the difference. The score range is from 1 to 7, with 1 indicating the least improvement and 7 indicating the greatest improvement in OIC symptoms.

    The number of subjects responding to each PGIC item at Visits 3 and/or 5 is presented for each treatment overall.


  5. Mean Change From Baseline at Visit 3/5 in Bowel Function Index (BFI) Questionnaire Scores to Compare the Impact of Movantik and PEG 3350 on OIC Symptoms [ Time Frame: From Baseline (Visit 2, Day 1) to Visit 3 (Day 15) and Visit 5 (Day 36). ]

    The BFI is a 3-item questionnaire administered by a study clinician to measure constipation from the subject's perspective (ease of defecation, feeling of complete evacuation, and personal judgment of constipation). For each item the subject was asked to rate their response on a scale from 0 to 100, where 0 indicates the best response (easy/no diffculty) and 100 the worst response (severe difficulty). The total BFI score was calculated as the mean of the 3 item scores.

    The mean change from baseline in BFI scores at Visits 3 and/or 5 are presented.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female between the ages of ≥18 and <85 years
  • Self-reported active symptoms of OIC (Opioid Induced Constipation) based on components of the Rome IV criteria at screening. Patients should have at least 2 of the following:

    • <3 SBMs (Spontaneous Bowel Movements) per week
    • Straining >25% of defecations
    • Sensation of incomplete evacuation >25% of defecations
    • Lumpy or hard stools >25% of defecations
    • Sensation of anorectal obstruction/blockage >25% of defecations
  • Confirmed OIC by BFI (Bowel Function Index) ≥30
  • Stable maintenance opioid regimen consisting of a total daily dose of at least 30 mg of oral morphine, or equivalent of 1 or more other opioid therapies
  • Willingness to stop all laxatives and other bowel regimens other than specified rescue medication

Exclusion Criteria:

  • Pain related to cancer or has a history of cancer within 5 years
  • Current constipation or chronic constipation not caused by or related to use of opioids
  • History of rectal evacuation disorders, surgery or procedures that can potentially affect pelvic floor function; requirement of using manual maneuvers to facilitate a bowel movement
  • Evidence of significant GI structural abnormalities, acute or chronic GI conditions that could post risk to the patient or confound the study results
  • Recent surgery that may affect GI motility or increase risk for bowel obstruction or perforation
  • Severe hepatic impairment
  • Moderate or severe renal impairment
  • Condition that may affect the permeability of blood-brain barrier
  • Concomitantly using strong or moderate CYP3A4 inhibitors and strong CYP3A4 inducers
  • Any other significant and/or progressive medical, surgical, psychiatric, or mental health condition or any significant laboratory findings that could increase the risk of participation in the study or affect the interpretation of study data as determined by the Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03060512


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Research Site
Huntsville, Alabama, United States, 35801
United States, Arizona
Research Site
Phoenix, Arizona, United States, 85020
Research Site
Phoenix, Arizona, United States, 85050
Research Site
Phoenix, Arizona, United States, 85051
United States, California
Research Site
Anaheim, California, United States, 92801
Research Site
Anaheim, California, United States, 92805
Research Site
Lincoln, California, United States, 95648
Research Site
Los Gatos, California, United States, 95032
Research Site
North Hollywood, California, United States, 91606
Research Site
Orange, California, United States, 92868
Research Site
San Diego, California, United States, 92114
Research Site
Westminster, California, United States, 92683
United States, Florida
Research Site
DeLand, Florida, United States, 32720
Research Site
Fort Myers, Florida, United States, 33912
Research Site
Jacksonville, Florida, United States, 32218
Research Site
Jacksonville, Florida, United States, 32257
Research Site
Jupiter, Florida, United States, 33458
Research Site
Lake City, Florida, United States, 32055
Research Site
Miami Springs, Florida, United States, 33166
Research Site
Miami, Florida, United States, 33155
Research Site
North Miami Beach, Florida, United States, 33162
Research Site
Ormond Beach, Florida, United States, 32174
Research Site
Plantation, Florida, United States, 33317
Research Site
Port Orange, Florida, United States, 32129
Research Site
West Palm Beach, Florida, United States, 33409
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30342
Research Site
Decatur, Georgia, United States, 30030
Research Site
Marietta, Georgia, United States, 30060
United States, Illinois
Research Site
Bloomington, Illinois, United States, 61701
United States, Indiana
Research Site
Brownsburg, Indiana, United States, 46112
United States, Maryland
Research Site
Pikesville, Maryland, United States, 21208
United States, Massachusetts
Research Site
Waltham, Massachusetts, United States, 02451
United States, Michigan
Research Site
Troy, Michigan, United States, 48085
Research Site
Wyoming, Michigan, United States, 49519
United States, Mississippi
Research Site
Biloxi, Mississippi, United States, 39531
United States, Missouri
Research Site
Saint Louis, Missouri, United States, 63141
United States, Nebraska
Research Site
Omaha, Nebraska, United States, 68114
United States, Nevada
Research Site
Las Vegas, Nevada, United States, 89119
United States, New Jersey
Research Site
Trenton, New Jersey, United States, 08611
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States, 87102
United States, New York
Research Site
Endwell, New York, United States, 13760
United States, North Carolina
Research Site
Charlotte, North Carolina, United States, 28204
Research Site
Greensboro, North Carolina, United States, 27410
Research Site
High Point, North Carolina, United States, 27262
Research Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Research Site
Beavercreek, Ohio, United States, 45432
United States, Oklahoma
Research Site
Edmond, Oklahoma, United States, 73034
United States, Pennsylvania
Research Site
Collegeville, Pennsylvania, United States, 19426
Research Site
Levittown, Pennsylvania, United States, 19056
United States, South Carolina
Research Site
Greer, South Carolina, United States, 29651
United States, Tennessee
Research Site
Chattanooga, Tennessee, United States, 37421
Research Site
Kingsport, Tennessee, United States, 37660
United States, Utah
Research Site
West Jordan, Utah, United States, 84088
Sponsors and Collaborators
AstraZeneca
QuintilesIMS, Inc.
Investigators
Layout table for investigator information
Study Director: AstraZeneca Scientific Leadership AstraZeneca
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] January 26, 2017
Statistical Analysis Plan  [PDF] August 15, 2017


Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03060512     History of Changes
Other Study ID Numbers: D3820L00017
First Posted: February 23, 2017    Key Record Dates
Results First Posted: July 13, 2018
Last Update Posted: July 13, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Opioid Induced constipation,
constipation,
laxative,
bowel movement,
Movantik,
Naloxegol
Additional relevant MeSH terms:
Layout table for MeSH terms
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms
Analgesics, Opioid
Naloxegol
Polyethylene glycol 3350
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Laxatives
Gastrointestinal Agents